Expression patterns in tissue at any stage of development.
Our IHC services are provided by the scientists who helped develop the low‑HER2 and PD‑L1 CDx assays. We deliver precise and impactful insights into biomarker development, therapeutic target validation, and prevalence, supporting programs from preclinical research through CDx development.
Decades of experience developing, validating and applying biomarker assays throughout every stage of development for leading biotech and pharma clients.
A technology agnostic approach to enable an unbiased selection of the most suitable platforms.
Global standardization and harmonization of assays including global clinical trial testing and our Biomarker Academy™ training programs with post-approval services.
Access to the world’s largest commercial biorepository to build optimal study cohorts.
We use a technology agnostic approach so you can choose the right technology for your project. Our expert scientists work with you consultatively to make sure your study is designed to achieve optimal outcomes.
